Kinnari Patel
President chez ROCKET PHARMACEUTICALS, INC.
Fortune : 11 M $ au 31/05/2024
Postes actifs de Kinnari Patel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Directeur des opérations | 04/01/2018 | - |
| Directeur Technique/Scientifique/R&D | 27/03/2024 | - | |
| President | - | - |
Historique de carrière de Kinnari Patel
Anciens postes connus de Kinnari Patel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Directeur des opérations | 01/01/2018 | 01/02/2021 |
| Conseiller Juridique Général | 01/04/2016 | 01/12/2017 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2010 | 01/04/2014 |
Formation de Kinnari Patel
| The Leonard N Stern School of Business | Masters Business Admin |
| University of the Sciences in Philadelphia | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Chief Operating Officer | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Kinnari Patel
- Expérience
